Filing Details

Accession Number:
0001104659-21-110547
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-27 16:15:32
Reporting Period:
2021-08-26
Accepted Time:
2021-08-27 16:15:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818382 Humacyte Inc. HUMA Biological Products, (No Disgnostic Substances) (2836) 851763759
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1878075 E Laura Niklason 2525 East North Carolina Highway 54
Durham NC 27713
President, Ceo And Director Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-26 1,148,240 $0.00 1,148,240 No 4 A Direct
Common Stock Acquisiton 2021-08-26 18,930,004 $0.00 18,930,004 No 4 A Indirect By Ayabudge LLC
Common Stock Acquisiton 2021-08-26 1,522,500 $10.00 20,452,504 No 4 P Indirect By Ayabudge LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Indirect By Ayabudge LLC
No 4 P Indirect By Ayabudge LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 262,596 $0.00 262,596 $1.19
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 13,129 $0.00 13,129 $2.56
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 157,558 $0.00 157,558 $2.56
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 262,596 $0.00 262,596 $3.44
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 131,298 $0.00 131,298 $6.54
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 1,312,984 $0.00 1,312,984 $10.28
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 1,575 $0.00 1,575 $10.28
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 13,129 $0.00 13,129 $2.56
Common Stock Stock Options (right to buy) Acquisiton 2021-08-26 17,068 $0.00 17,068 $6.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
262,596 2023-11-22 No 4 A Direct
13,129 2025-09-01 No 4 A Direct
157,558 2026-03-09 No 4 A Direct
262,596 2026-09-14 No 4 A Direct
131,298 2028-04-12 No 4 A Direct
1,312,984 2021-11-09 2031-01-14 No 4 A Direct
1,575 2021-12-14 2030-12-14 No 4 A Direct
13,129 2025-09-01 No 4 A Indirect
17,068 2028-04-12 No 4 A Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 810,161 Indirect By Spouse
Footnotes
  1. On August 26, 2021 , Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
  2. Options are fully vested and exercisable.
  3. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
  4. One-third of the option will vest on each of the three anniversaries after November 9, 2020.
  5. Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.